Literature DB >> 31186760

IL-6 and miR-1271 expression levels in elderly and young gastric cancer patients and correlation analysis with prognosis.

Shixiong Liu1, Yun Zhou1, Li Zhao2, Jing Wang1, Rui Ji3, Yiqing Wang1, Jiyin Wu1, Xiang Yan1.   

Abstract

Differences in inflammatory factors IL-6 and miR-1271 expression levels between elderly and young gastric cancer patients were investigated. A retrospective analysis of 146 cases of gastric cancer tissue and normal fresh tissue specimens diagnosed in The First Hospital of Lanzhou University from January 2013 to January 2015, was performed. Patients aged ≥60 years were the elderly group (76 cases), and patients ≤40 years were the youth group (70 cases). RT-qPCR was used to detect the relative expression levels of IL-6 and miR-1271, and Kaplan-Meier for a postoperative 3-year survival analysis of young and elderly gastric cancer patients. The expression level of IL-6 and miR-1271 was significantly higher in young gastric cancer tissues than that in elderly gastric cancer tissues (P<0.001). The expression levels of IL-6 and miR-1271 were correlated with age, tumor size, lymph node metastasis, distant metastasis, clinical stage and differentiation degree of gastric cancer patients (P<0.05). The 3-year overall survival rate of patients with a low expression of IL-6 and miR-1271 was better than that of patients with a high expression in young and elderly gastric cancer (P<0.05). IL-6 was highly expressed but miR-1271 expression was low in gastric cancer tissues. The 3-year overall survival rate of patients with the low expression of IL-6 was better than that of patients with the high expression in young and elderly gastric cancer. The high expression of miR-1271 was better than that of patients with the low expression in young and elderly gastric cancer. Findings of the present study provide data support for the clinical evaluation of differences between young and elderly gastric cancer and their prognosis.

Entities:  

Keywords:  IL-6; elderly gastric cancer; miR-1271; prognosis; young gastric cancer

Year:  2019        PMID: 31186760      PMCID: PMC6507464          DOI: 10.3892/ol.2019.10230

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


Introduction

Gastric cancer, a common digestive tract tumor worldwide, has high grade malignancy and mortality (1,2). Its age of onset is mostly around 60 years, and the incidence increases with age. It has been shown that the incidence of cancer in today's society is tending to be younger (3). In addition, the clinical and pathological features of elderly gastric cancer are quite different from those of young gastric cancer (4). Elderly gastric cancer usually has low-grade malignancy and high differentiation, making the prognosis of elderly gastric cancer patients slightly better than that of young gastric cancer patients (5). The physical fitness of the youth population is mostly good, with a small number of physical examinations and medical treatments per year; thus, the proportion of young patients diagnosed as advanced gastric cancer at the time of initial diagnosis is higher (6). However, the current claim that the prognosis of elderly gastric cancer is superior to that of young gastric cancer remains controversial. It has been reported in the literature that miRNAs are involved in cell proliferation, apoptosis, differentiation and embryonic development (7). In recent years, medical workers have gradually taken the relationship between miRNAs and tumors as a research hotspot (8). However, miR-1271 has rarely been studied on tumors. Only a few related studies have shown that miR-1271 has a low expression in non-small cell lung cancer and is correlated with the poor prognosis of cancer (9). Having diverse and complex functions, IL-6 plays an important role in tumor processes, inflammation and immune responses (10). IL-6 has been reported in the literature to be used as an indicator to predict the prognosis of gastric cancer (11). Currently, the population of the world is developing with an aging trend (12), and chronic inflammation is closely related to the increase of age. Inflammation can promote cell aging, which in turn can produce inflammatory factors (13,14). According to reports in the literature, the high level of pro-inflammatory factor interleukin-6 (IL-6) in the body, associated with cognitive dysfunction, cardiovascular disease and brain atrophy in the elderly, can be used as a reference standard for inflammatory aging (15–17). The aim of this study was to investigate differences in the inflammatory factors IL-6 and miR-1271 expression levels between elderly and young gastric cancer patients and their correlation with prognosis, providing data support for the clinical evaluation of the prognosis of gastric cancer.

Materials and methods

General information

A retrospective analysis of each of 146 cases of gastric cancer tissue and normal fresh tissue specimens at 50 mm adjacent to the cancer, surgically resected and first diagnosed in The First Hospital of Lanzhou University (Lanzhou, China) from January 2013 to January 2015, was performed. The age range was 28–75 years, and patients ≥60 years were placed in the elderly group (76 cases), while those ≤40 years in the youth group (70 cases). There was a significant difference between the two groups in age (P<0.001), but no significant difference in sex, tumor size, lymph node metastasis, distant metastasis, clinical stage and differentiation degree (P>0.05). Specimens were immediately stored in liquid nitrogen after resection, and then transferred to a refrigerator at −80°C. All cancer tissue specimens were confirmed by gastroscope pathology. According to the results of CT, radical gastrectomy could be performed. Adjacent tissues were confirmed without obvious cancer cells and inflammatory cell infiltrations. In this study, patients aged 40–60 years with gastric cancer were excluded. None of the patients had a past history of tumors, liver, kidney, other organ dysfunction, abnormal bleeding or coagulation disorder dysfunction. Patients were included with complete medical records and follow-up data and without radiotherapy, chemotherapy or other anticancer treatments before operation (Table I).
Table I.

Comparison of general information between the two groups of patients [n (%)].

FactorElderly group (n=76)Youth group (n=70)t/χ2 valueP-value
Age68.72±5.6630.54±8.8331.35<0.001
Sex0.1040.863
  Male48 (63.16)46 (65.71)
  Female28 (36.84)24 (34.29)
Tumor size0.6150.506
  ≥5 cm32 (42.11)34 (48.57)
  <5 cm44 (57.89)36 (51.43)
Lymph node metastasis1.3290.320
  Yes34 (44.74)38 (54.29)
  No42 (55.26)32 (45.71)
Distant metastasis2.5200.151
  Yes19 (25.00)26 (37.14)
  No57 (75.00)44 (62.86)
Clinical stage1.1680.312
  I+II49 (64.47)39 (55.71)
  III+IV27 (35.53)31 (44.29)
Differentiation degree1.9890.173
  Low-medium52 (68.42)40 (57.14)
  High24 (31.58)30 (42.86)
The study was reviewed by the Ethics Committee of The First Hospital of Lanzhou University. All patients and their families were informed and signed the consent form.

Reagents and instruments

ELISA kit of IL-6 was purchased from Beijing Yuetai Technology Co., Ltd., Beijing, China; TRIzol reagent for RNA extraction from Shanghai Pufei Biotechnology Co., Ltd., Shanghai, China; TaqMan MicroRNA assay from Applied Biosystems, Foster City, CA, USA; Nanodrop 2000 UV spectrophotometer from Thermo Fisher Scientific, Inc., Waltham, MA, USA; Countess II FL Automated Cell Counter real-time PCR instrument from Applied Biosystems; and Antus PHOMO automatic microplate reader from Jinan Yuteng Biotechnology Co., Ltd., Jinan, China.

Total RNA extraction

One-step extraction was used to extract the total RNA from gastric cancer tissues and adjacent tissues with TRIzol reagent. The specific steps were in strict accordance with the protocol. The Nanodrop 2000 UV spectrophotometer was used to detect the extracted RNA concentration and purity, and agarose gel electrophoresis to detect its integrity.

Reverse transcription reaction

Reverse transcription was performed on the extracted RNA to obtain cDNA that was used as a template to carry out experiments. Primer sequences were designed and produced by Baoriyi Biotechnology (Beijing) Co., Ltd., Beijing, China, with U6 as an internal reference gene in this experiment. A total of 20 µl of the reverse transcription system was used as follows: 2 µl of total RNA, 1 µl of miRNA RT enzyme mix, 10 µl of 2X TS miRNA reaction mix, and RNase-free water supplemented to 20 µl. Reaction conditions were: incubation at 37°C for 1 h then mixing, heating at 85°C for 5 sec to inactivate RT enzyme mix, and the synthesized cDNA was stored at 4°C.

RT-qPCR detection of gene expression

A total of 20 µl of the real-time PCR system was prepared in accordance with the protocol: 1 µl of cDNA (dilution at a ratio of 1:10), 0.4 µl of forward primer, 0.4 µl of Universal miRNA qPCR Primer, 10 µl of Tip Green qPCR SuperMix, and ddH2O supplemented to 20 µl. PCR amplification was performed using a Countess II FL Automated Cell Counter real-time PCR instrument. Reaction conditions were: at 94°C for 30 sec, at 94°C for 5 sec, and at 60°C for 30 sec, for a total of 40 cycles. The PCR product was stored at 4°C, with U6 as a reaction internal reference gene. Each group of samples was repeated 3 times. The 2−∆Cq method was used to analyze the expression level of miR-1271 in specimens (18). Primer sequences are shown in Table II.
Table II.

miR-1271 primer and internal reference sequence.

Gene nameUpstream primerDownstream primer
miR-12715′-CAGCACTTGGCACCTAGCA-3′5′-TATGGTTGTTCTCCTCTCTGTCTC-3′
U65′-CTCGCTTCGGCAGCACA-3′5′-AACGCTTCACGAATTTGCGT-3′

ELISA detection of IL-6 expression level

Gastric cancer tissue (100 g) was taken, with 5 ml of PBS solution added, to prepare homogenate in an ice-water suspension. It was centrifuged at 10,600 × g for 5 min at 4°C, with the supernatant taken for use. ELISA was used to detect IL-6 levels in gastric cancer tissues and adjacent tissues, and an automatic microplate reader to detect the OD value of each well at a wavelength of 450 nm, to calculate IL-6 concentration. The specific operation was carried out in strict accordance with the protocol. The determination was repeated 3 times to obtain the average value.

Statistical analysis

SPSS 21.0 statistical software package (Shanghai Kabei Information Technology Co., Ltd., Shanghai, China) was used to statistically analyze the data. Measurement data are expressed as mean ± standard deviation (mean ± SD). Analysis of variance was used for measurement data in accordance with the normal distribution, Kaplan-Meier for survival analysis, and log-rank test for comparison of the survival rate. P<0.05 was considered to indicate a statistically significant difference.

Results

Expression levels of IL-6 and miR-1271 in gastric cancer and adjacent tissues

The expression level of IL-6 was significantly higher in young and elderly gastric cancer tissues than that in adjacent tissues, with a statistically significant difference (P<0.001). That of IL-6 was significantly lower in young gastric cancer tissues than that in elderly gastric cancer tissues, with a statistically significant difference (P<0.001). The expression level of miR-1271 was significantly lower in young and elderly gastric cancer tissues than that in adjacent tissues, with a statistically significant difference (P<0.001). That of miR-1271 was significantly higher in young gastric cancer tissues than that in elderly gastric cancer tissues, with a statistically significant difference (P<0.001) (Table III).
Table III.

Expression levels of IL-6 and miR-1271 in gastric cancer tissues and adjacent tissues.

GroupnIL-6miR-1271
Adjacent tissues1461.23±0.153.06±0.26
Elderly gastric cancer tissues  764.65±0.34[a]1.04±0.09[a]
Young gastric cancer tissues  703.12±0.21[a,b]1.82±0.18[a,b]
F value2042.002399.00
P-value<0.001<0.001

P<0.001, compared with adjacent tissues

P<0.001, compared with elderly gastric cancer tissues.

Correlation of IL-6 and miR-1271 expression levels with clinical and pathological features

The expression levels of IL-6 and miR-1271 were not significantly correlated with sex (P>0.05), but correlated with age, tumor size, lymph node metastasis, distant metastasis, clinical stage and differentiation degree of gastric cancer patients (P<0.05). The expression level of IL-6 was high, but that of miR-1271 was low in patients with older age, larger tumor size, lymph node metastasis, distant metastasis, the clinical stage of III–IV and low differentiation degree (Table IV).
Table IV.

Correlation of IL-6 and miR-1271 expression levels with clinical and pathological features.

FactornIL-6t valueP-valuemiR-1271t valueP-value
Age (years)32.990<0.00132.680<0.001
  ≥60764.65±0.341.04±0.09
  ≤40703.12±0.211.82±0.18
Sex  0.6740.501  1.3820.169
  Male943.64±0.281.62±0.11
  Female523.61±0.211.65±0.15
Tumor size  2.5990.010  2.2370.027
  ≥5 cm663.57±0.261.42±0.15
  <5 cm803.46±0.251.48±0.17
Lymph node metastasis18.080<0.00124.960<0.001
  Yes724.03±0.291.14±0.13
  No743.31±0.181.79±0.18
Distant metastasis25.610<0.00124.060<0.001
  Yes454.58±0.371.01±0.08
  No1013.24±0.251.65±0.17
Clinical stage17.630<0.00123.820<0.001
  I+II883.67±0.281.83±0.19
  III+IV584.62±0.371.15±0.13
Differentiation degree24.010<0.00125.830<0.001
  Low-medium924.33±0.311.24±0.10
  High543.21±0.191.86±0.19

Correlation of expression levels of IL-6 and miR-1271 with young and elderly gastric cancer

The median expression levels of IL-6 and miR-1271 in young gastric cancer patients were 3.11±0.21 and 1.84±0.14, respectively (data not shown). Based on this, the high and low expression levels of the two indicators IL-6 and miR-1271 were established, respectively, each with 35 cases. The 3-year overall survival rate of patients with a low expression of IL-6 was better than that of patients with a high expression in young gastric cancer (P<0.05). Survival of patients with a high expression of miR-1271 was better than that of patients with a low expression in young gastric cancer (P<0.05). The median expression levels of IL-6 and miR-1271 in elderly gastric cancer patients were 4.63±0.24 and 1.05±0.06, respectively (data not shown). Based on this, the high and low expression levels of the indicators IL-6 and miR-1271 were established, respectively, each with 38 cases. The 3-year overall survival rate of patients with low expression of IL-6 was better than that of patients with high expression in elderly gastric cancer patients (P<0.05). That of patients with the high expression of miR-1271 was better than that of patients with the low expression in elderly gastric cancer patients (P<0.05) as per the Kaplan Meier analysis and log-rank test (Figs. 1 and 2, and Table V).
Figure 1.

Correlation of expression levels of IL-6 and miR-1271 with prognosis of young gastric cancer. The results of Kaplan-Meier survival curve showed that the 3-year overall survival rate of patients with the low expression of IL-6 was better than that of patients with the high expression in young gastric cancer (P=0.043). Survival of patients with high expression of miR-1271 was better than that of patients with the low expression in young gastric cancer (P=0.025).

Figure 2.

Correlation of expression levels of IL-6 and miR-1271 with prognosis of elderly gastric cancer. The results of Kaplan-Meier survival curve showed that the 3-year overall survival rate of patients with the low expression of IL-6 was better than that of patients with the high expression in elderly gastric cancer (P=0.021). Survival of patients with the high expression of miR-1271 was better than that of patients with the low expression in elderly gastric cancer (P=0.047).

Table V.

Correlation of expression levels of IL-6 and miR-1271 with young and elderly gastric cancer.

IndicatorSurvival rate [(n)%]


Groupn1 year2 years3 yearsP-value
Youth groupIL-6Low expression3529 (82.86)25 (71.43)18 (51.43)0.043
High expression3524 (68.57)17 (48.57)10 (28.57)
miR-1271Low expression3525 (71.43)15 (42.86)  9 (25.71)0.025
High expression3528 (80.00)24 (68.57)16 (45.71)
Elderly groupIL-6Low expression3834 (89.47)29 (76.32)21 (55.26)0.021
High expression3828 (73.68)23 (60.53)12 (31.58)
miR-1271Low expression3827 (71.05)21 (55.26)10 (26.32)0.047
High expression3832 (84.21)26 (68.42)18 (47.37)

Discussion

Gastric cancer accounts for 10.4% of the total number of cancer deaths in Western countries (19). Currently, it is a comprehensive treatment based on surgery, but its local recurrence rate following surgery is still as high as 50%, with poor postoperative survival rate (20). The formation of tumors mainly depends on the activation of proto-oncogenes and mutation of tumor suppressor genes. The development mechanism of gastric cancer has not yet been clarified, owing to the abnormal lack of specificity of the genes (21). Nurul-Syakima et al (22) found that miR-1271 is highly expressed in head and neck tumors, but Maurel et al (23) reported a low expression in hepatoma cells, exerting a tumor suppressor effect. In this study, the expression level of miR-1271 was significantly lower in young and elderly gastric cancer tissues than that in adjacent tissues, with a statistically significant difference (P<0.001). That of miR-1271 was significantly higher in young gastric cancer tissues than that in elderly gastric cancer tissues, with a statistically significant difference (P<0.001). In addition, miR-1271 was not significantly correlated with sex (P>0.05), but was correlated with age, tumor size, lymph node metastasis, distant metastasis, clinical stage and differentiation degree of gastric cancer patients (P<0.05). Taken together, the above results indicate that the expression levels and roles of miR-1271 are different in different tumors, tissues and cells. The study of Xiang et al (24) shows that miR-1271 expression is low in gastric cancer tissues of most patients, and is negatively correlated with tumor size and clinical stage. Those findings are consistent with our results. In this study, data of the correlation analysis of miR-1271 with the clinical pathology of gastric cancer were presented as mean standard deviation, but as the number of cases in the studies were different, this may result in statistically significant differences due to different statistical calculation methods. Our study showed that the expression level of IL-6 was significantly higher in young and elderly gastric cancer tissues than that in adjacent tissues, with a statistically significant difference (P<0.001). That of IL-6 was significantly lower in young gastric cancer tissues than that in elderly gastric cancer tissues, with a statistically significant difference (P<0.001). That of IL-6 was not significantly correlated with sex (P>0.05), but correlated with age, tumor size, lymph node metastasis, distant metastasis, clinical stage and differentiation degree of gastric cancer patients (P<0.05). The expression level of IL-6 was higher in elderly gastric cancer than that in young gastric cancer, probably because the elderly usually have low immune function, susceptible to inflammatory infections (25). Sampaio et al (26) found that IL-6, highly expressed in gastric cancer tissues, is correlated with tumor size and the T stage of gastric cancer. The results of this study are consistent with those of Sampaio et al (26). In this study, the data of the correlation analysis of IL-6 with the clinical pathology of gastric cancer were presented as mean standard deviation. According to reports in the literature, IL-6 affects the growth of tumor cells and the development of the disease (27). It also promotes angiogenesis, and the adhesion and invasion of tumor cells (28). The 3-year overall survival rate of patients with the low expression of IL-6 was better than that of patients with the high expression in young and elderly gastric cancer (P<0.05). Survival of patients with the high expression of miR-1271 was better than that of patients with the low expression in young and elderly gastric cancer (P<0.05). Since no study of the correlation of IL-6 and miR-1271 with the prognosis of young and elderly gastric cancer was found, the results of this study cannot be compared with those of other studies. In summary, IL-6 is highly expressed but miR-1271 is lowly expressed in gastric cancer tissues, and the expression levels of both are correlated with age, tumor size, lymph node metastasis, distant metastasis, clinical stage and differentiation degree of gastric cancer patients. The 3-year overall survival rate of patients with the low expression of IL-6 is better than that of patients with the high expression in young and elderly gastric cancer. Survival of patients with high expression of miR-1271 is better than that of patients with low expression in young and elderly gastric cancer.
  27 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Clinicopathologic characteristics of gastric carcinoma in elderly patients: a comparison with young patients.

Authors:  Dong-Yi Kim; Jae-Kyoon Joo; Seong-Yeob Ryu; Young-Kyu Park; Young-Jin Kim; Shin-Kon Kim
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

3.  Cytokine loops driving senescence.

Authors:  Jiri Bartek; Zdenek Hodny; Jiri Lukas
Journal:  Nat Cell Biol       Date:  2008-08       Impact factor: 28.824

Review 4.  The role of cytokines in classical Hodgkin lymphoma.

Authors:  Brian F Skinnider; Tak W Mak
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

5.  Establishment and characterization of EB virus-free normal B-lymphocyte and interleukin-6-producing poorly differentiated adenocarcinoma cell lines derived from gastric tumor tissue.

Authors:  Satoshi Ohi; Hisashi Hashimoto; Toshiaki Tachibana; Isao Tabei; Masako Nakajima; Kahei Sato; Katsuhiko Yanaga; Hiroshi Ishikawa
Journal:  Hum Cell       Date:  2005-03       Impact factor: 4.174

6.  Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor.

Authors:  Tatsuto Ashizawa; Ryosuke Okada; Yoshiaki Suzuki; Makoto Takagi; Tatsuyuki Yamazaki; Tetsuo Sumi; Toshiaki Aoki; Shinobu Ohnuma; Tatsuya Aoki
Journal:  Gastric Cancer       Date:  2005       Impact factor: 7.370

7.  Correlation between serum levels of interleukin-6 and vascular endothelial growth factor in gastric carcinoma.

Authors:  Shih-Pei Huang; Ming-Shiang Wu; Hsiu-Po Wang; Chang-Shiu Yang; Min-Liang Kuo; Jaw-Town Lin
Journal:  J Gastroenterol Hepatol       Date:  2002-11       Impact factor: 4.029

8.  Proinflammatory cytokine-induced cellular senescence of biliary epithelial cells is mediated via oxidative stress and activation of ATM pathway: a culture study.

Authors:  Motoko Sasaki; Hiroko Ikeda; Yasunori Sato; Yasuni Nakanuma
Journal:  Free Radic Res       Date:  2008-06-25

9.  Gastric cancer development in mice lacking the SHP2 binding site on the IL-6 family co-receptor gp130.

Authors:  Louise M Judd; Barbara M Alderman; Meegan Howlett; Arthur Shulkes; Chris Dow; Jill Moverley; Diane Grail; Brendan J Jenkins; Matthias Ernst; Andrew S Giraud
Journal:  Gastroenterology       Date:  2004-01       Impact factor: 22.682

Review 10.  The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer.

Authors:  Willscott E Naugler; Michael Karin
Journal:  Trends Mol Med       Date:  2008-02-07       Impact factor: 11.951

View more
  1 in total

1.  Serum IL-6 Level Predicts the Prognosis and Diagnosis in Cervical Cancer Patients.

Authors:  Chunyan Cai; Xing Peng; Yumei Zhang
Journal:  Int J Womens Health       Date:  2022-05-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.